A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effects of SOtagLiflozin on Clinical Outcomes in HemodynamIcally STable Patients with Type 2 Diabetes POST Worsening Heart Failure

About this Study

We are doing this study to learn more about heart failure and diabetes and to see if an FDA approved diabetes medication called sotagliflozin improves cardiovascular outcomes in people with heart failure and diabetes.

Sponsor Protocol ID:EFC15156
IRB Number:2019-0149
Actively Enrolling
Interventional
Phase 3
June 24, 2019
Eligibility Criteria
18 years old
85 years old
Both Male and Female
No
No
Yes

Inclusion Criteria

Exclusion CriteriaE 01. Age

Categories Click category to view its trials.
Heart Health
Participating Locations
Jackson Medical Mall - UMMC Clinics
Pavilion - UMMC
University Hospital - UMMC
Contact Information
Contact Name: Theresa Hickey Hutson
Phone Number: 601-815-8702
Email: tlhickey@umc.edu
Principal Investigator:Charles Moore
How to participate in our Clinical Trials